title: Clinical implication of centrosome amplification in plasma cell neoplasm.
abstract: The mechanisms underlying aneuploidy in multiple myeloma (MM) are unclear. Centrosome amplification has been implicated as the cause of chromosomal instability in a variety of tumors and is a potential mechanism causing aneuploidy in MM. Using immunofluorescent (IF) staining, centrosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS). We also investigated the gene expression of centrosome proteins. Overall, gene expression data correlated well with IF-detected centrosome amplification, allowing us to derive a gene expression-based centrosome index (CI) as a surrogate for centrosome amplification. Clinically, MM patients with high CI (> 4) are associated with poor prognostic genetic and clinical subtypes (chromosome 13 deletion, t(4; 14), t(14;16), and PCLI > 1%, P < .05) and are shown here to have short survival (11.1 months versus 39.1 months, P < .001). On multivariate regression, a high CI is an independent prognostic factor. Given that centrosome amplification is already observed in MGUS and probably integral to early chromosomal instability and myeloma genesis, and patients with more extensive centrosome amplification have shorter survival, the mechanisms leading to centrosome amplification should be investigated because these may offer new avenues for therapeutic intervention.
authors.affiliation: Division of Hematology-Oncology, Mayo Clinic, Johnson Research Bldg, 13400 E Shea Blvd, Scottsdale, AZ, USA.
authors.forename: Wee J
authors.initials: WJ
authors.lastname: Chng
authors.forename: Greg J
authors.initials: GJ
authors.lastname: Ahmann
authors.forename: Kim
authors.initials: K
authors.lastname: Henderson
authors.forename: Rafael
authors.initials: R
authors.lastname: Santana-Davila
authors.forename: Philip R
authors.initials: PR
authors.lastname: Greipp
authors.forename: Morie A
authors.initials: MA
authors.lastname: Gertz
authors.forename: Martha Q
authors.initials: MQ
authors.lastname: Lacy
authors.forename: Angela
authors.initials: A
authors.lastname: Dispenzieri
authors.forename: Shaji
authors.initials: S
authors.lastname: Kumar
authors.forename: S Vincent
authors.initials: SV
authors.lastname: Rajkumar
authors.forename: John A
authors.initials: JA
authors.lastname: Lust
authors.forename: Robert A
authors.initials: RA
authors.lastname: Kyle
authors.forename: Steven R
authors.initials: SR
authors.lastname: Zeldenrust
authors.forename: Suzanne R
authors.initials: SR
authors.lastname: Hayman
authors.forename: Rafael
authors.initials: R
authors.lastname: Fonseca
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000782:Aneuploidy; D018385:Centrosome / Q000648:ultrastructure*; D003598:Cytoskeletal Proteins / Q000235:genetics; D005260:Female; D015870:Gene Expression; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics; D010265:Paraproteinemias / Q000235:genetics; D010950:Plasma Cells / Q000648:ultrastructure; D010954:Plasmacytoma / Q000235:genetics* / Q000648:ultrastructure*; D011003:Ploidies; D011379:Prognosis
chemical_list: D003598:Cytoskeletal Proteins